Rev08

1   **Type of Article:** *Short Communication*

2

3   **Title:** NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways

4   against SARS-CoV-2 challenge

5

6   **Authors and Affiliations:**

7   Mimi Guebre-Xabier[1 #], Nita Patel[1 #], Jing-Hui Tian[1], Bin Zhou[1], Sonia Maciejewski[1],

8   Kristal Lam[1], Alyse D. Portnoff[1], Michael J. Massare[1], Matthew B. Frieman[2], Pedro A.

9   Piedra[3], Larry Ellingsworth[1], Gregory Glenn[1], and Gale Smith[1] *

10

11   [1]Novavax, Inc. 21 Firstfield Road, Gaithersburg, MD, 20878, USA. mguebre-

12   xabier@Novavax.com (M.G.X.), npatel@novavax.com (N.P.), jhtian@Novavax.com

13   (J.H.T.), bzhou@Novavax.com (B.Z.), smaciejewski@Novavavax.com (S.M.),

14   klam@Novavax.com (K.L.), aportnoff@Novavax.com (A.D.P.),

15   mmassare@Novavax.com (M.J.M.), lellingsworth@novavax.com (L.E.),

16   gglenn@Novavax.com (G.G.), gsmith@Novavax.com (G.S.)

17   [2]University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD

18   21201, USA. mfrieman@som.umaryland.edu (M.B.F.)

19   [3]Department of Molecular Virology and Microbiology, and Pediatrics, Baylor College of

20   Medicine, Houston, Texas. ppiedra@bcm.edu (P.A.P.)

21

22   *****Correspondence**: Dr. Gale Smith, Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD

23   20878 USA. +1-240-268-2000. gsmith@Novavax.com (G.S.)

24   [#]MGX and NP each contributed equally as co-lead authors.

Rev08

Highlights

25

26 • Full-length SARS-CoV-2 prefusion spike with Matrix-M1™ (NVX-CoV2373) vaccine.

27 • Induced hACE2 receptor blocking and neutralizing antibodies in macaques.

28 • Vaccine protected against SARS-CoV-2 replication in the nose and lungs.

29 • Absence of pulmonary pathology in NVX-CoV2373 vaccinated macaques.

30

Rev08

31 ABSTRACT

32 There is an urgent need for a safe and protective vaccine to control the global spread of

33 SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and

34 protective efficacy of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) produced from

35 the full-length SARS-CoV-2 spike (S) glycoprotein stabilized in the prefusion

36 conformation. Cynomolgus macaques (*Macaca fascicularis*) immunized with NVX-

37 CoV2373 and the saponin-based Matrix-M adjuvant induced anti-S antibody that was

38 neutralizing and blocked binding to the human angiotensin-converting enzyme 2

39 (hACE2) receptor. Following intranasal and intratracheal challenge with SARS-CoV-2,

40 immunized macaques were protected against upper and lower infection and pulmonary

41 disease. These results support ongoing phase 1/2 clinical studies of the safety and

42 immunogenicity of NVX-CoV2327 vaccine (NCT04368988).

43 **Key words:** SARS-CoV-2, COVID-19, spike glycoprotein, NVX-CoV2373 nanoparticles,

44 Matrix-M1 adjuvant, nonhuman primate

Rev08

1. INTRODUCTION

46 There is an urgent need for a safe and effective severe acute respiratory syndrome

47 coronavirus 2 (SARS-CoV-2) vaccine to prevent coronavirus disease 2019 (Covid-19).

48 We have developed a recombinant nanoparticle vaccine constructed from the

49 full-length, wild-type SARS-CoV-2 spike glycoprotein (GenBank gene sequence

50 MN908947, nucleotides 21563-25384) optimized for the baculovirus-*Spodoptera*

51 *frugiperda* (Sf9) insect cell expression system [1]. In mice and nonhuman primates

52 (NHP), NVX-CoV2373 with a Matrix-M1 saponin-based adjuvant induced high titer anti-

53 spike IgG that blocks binding to the hACE2 receptor, neutralize wild type virus, and

54 protects mice against SARS-CoV-2 challenge with no evidence of vaccine-associated

55 enhanced respiratory disease. NVX-CoV2373 vaccine also induces polyfunctional CD4$^+$

56 T-cell responses of IFN-γ, IL-2, and TNF-α biased towards a Th1 phenotype, and

57 generates antigen-specific germinal center B cells in the spleen. Safety and

58 immunogenicity NVX-CoV2327 vaccine is currently under evaluation in humans

59 (NCT04368988) and primary safety and immunogenicity outcomes described [2]. We

60 evaluate in the current study NVX-CoV2373 vaccine immunogenicity, induction of

61 receptor blocking, and neutralizing antibodies compared to levels in human COVID-19

62 convalescent sera. And in a nonhuman primate challenge model, protection against

63 upper and lower virus replication and pulmonary disease.

2. MATERIALS AND METHODS

65 *2.1.   Cell lines, virus, antibody reagents, and receptors.*

4

66   Vero E6 cells (ATCC, CRL-1586) were maintained in Minimal Eagles Medium (MEM)

67   supplemented with 10% fetal bovine serum, 1% glutamine and 1% penicillin and

68   streptomycin. The SARS-CoV-2 (WA-1, 2020) isolated was obtained from the Center for

69   Disease Control and stock virus prepared in Vero E6 cells. Histidine-tagged hACE2

70   receptor was purchased from Sino Biologics (Beijing, CN). Rabbit anti-SARS-CoV spike

71   protein was purchased form Biodefense and Emerging Infections Research Resources

72   Repository (BEI Resources, Manassas, VA).

73   2.2. *Recombinant SARS-CoV-2 spike protein*

74   NVX-CoV2327 was codon optimized synthetically produced from the full-length S

75   glycoprotein gene sequence (GenBank MN908947 nucleotides 21563-25384) for

76   expression in *Spodoptera frugiperda* (Sf9) cells (GenScript Piscataway, NJ, USA) as

77   describe [1]. Briefly, the S1/S2 furin cleavage site 682-RRAR-685 was modified 682-

78   QQAQ-685 and two proline substitutions introduced at positions K986P and V987P (2P)

79   to stabilize the full-length SARS-CoV-2 S [3].

80   *2.3. Animal ethics*

81   The in-life portion of the study was conducted at BIOQUAL, Inc (Rockville, MD).

82   Female and male, > 3 years old at study initiation, cynomolgus macaques (*Macaca*

83   *fascicularis*) were obtained from Primgen, Inc (Hines, IL) and maintained at BIOQUAL,

84   Inc for the entire in-life portion of the study. BIOQUAL, Inc. is accredited by AAALACC

85   International. Animals were maintained and treated according to the Institutional

86   Biosafety Committee guidelines and the study was pre-approved by the Institutional

87   Animal Care and Use Committee (IACUC). The study was conducted in accordance

Rev08

88   with the National Institutes of Health Guide for Care and Use of Laboratory Animals

89   (NIH publication 8023, Revised 1978).

90   *2.4.   Cynomolgus macaque immunization*

91   Cynomolgus macaques >3 years old (n=4/group) at study initiation received 5 or

92   25 µg NVX-CoV2327 with 50 µg Matrix-M1 (Novavax AB, Uppsala, Sweden)

93   administered in 500 µL in the thigh muscle in two doses spaced 21 days apart. A

94   separate group was immunized with a factional dose (2.5 µg) NVX-CoV2373 with 25 µg

95   Matrix-M1 in two doses spaced 21 days apart and a placebo group received formulation

96   buffer. Serum was collected before immunization on Day 0, Day 21 just prior to the

97   second immunization, and Day 33.

98   *Anti-spike (S) IgG ELISA*

99   Anti-SARS-CoV-2 spike (S) protein IgG ELISA titers were measured as described

100   [1]. Anti-S IgG EC_{50} titers were calculated by 4-parameter fitting using SoftMax Pro

101   6.5.1 GxP software. Individual animal anti-S IgG EC_{50} titers, group geometric mean

102   titers (GMT) were plotted using GraphPad Prism 7.05 software.

103   *2.5.   Inhibition of hACE2 receptor binding and neutralization*

104   Antibodies that block binding of hACE2 receptor to the S-protein and neutralize in a

105   cytopathic effect assay (CPE) in Vero E6 cells were measured as described previously

106   as the serum titer that blocks 100% CPE [1]. Serum antibody titer at 50% binding

107   inhibition (IC_{50}) of hACE2 to SARS-CoV-2 S protein was determined in the SoftMax Pro

108   program. Individual animal hACE2 receptor inhibiting titers, mean titers, and SEM were

109   plotted using GraphPad Prism 7.05 software. Neutralizing antibody titers were

6

Rev08

110   determined as the dilution of serum that inhibited 100% of CPE (CPE_{100}) at 3 days post

111   infection of Vero E6 cells in a 96 well plate format.

2.6.   SARS-CoV-2 challenge procedure

113   The virus challenge study was done at BIOQUAL, Inc. within a BSL-3 containment

114   facility. SARS-CoV-2 generated from isolate 2019-nCoV/USA-WA1/2020 was received

115   from BEI Resources (NR-52281; lot # 70033175) and expanded in Vero E6 cells for

116   challenge stock generation. Animals were sedated and challenged with a targeted total

117   dose of 1.04 x 10^4 pfu SARS-CoV-2 by intranasal (IN) and intratracheal (IT) in a volume

118   of 0.25 mL each route. BAL and nasal swabs were collected 2- and 4-days post

119   challenge. Necropsy was performed 7 days following challenge and lung tissues

120   collected for histopathology.

2.7.   RNA subgenomic RT-PCR

122   The subgenomic viral mRNA (sgRNA) was measured in macaque bronchoalveolar

123   lavage (BAL) and nasal swabs collected 2- and 4-days post challenge using RT-PCR as

124   described [4]. To generate a standard curve, the SARS-CoV-2 E gene sgRNA was

125   cloned into a pcDNA3.1 expression plasmid. The insert was transcribed using an

126   AmpliCap-Max T7 High Yield Message Maker Kit (Cellscript, Madison, WI) to obtain

127   RNA for standards. Prior to RT-PCR, samples collected from challenged animals or

128   standards were reverse-transcribed using Superscript III VILO (Invitrogen) according to

129   the manufacturer's instructions. A Taqman custom gene expression assay

130   (ThermoFisher Scientific, Rockville, MD) was designed using the sequences targeting

131   the E gene sgRNA. Reactions were carried out on a Quant Studio 6 and 7 Flex Real-

7

Rev08

132   Time PCR System (Applied Biosystems, Foster City, CA) according to the

133   manufacturer's specifications. Standard curves were used to calculate sgRNA in copies

134   per mL. The quantitative assay was sensitive to 50 copies per mL.

135   *2.8.   Human COVID-19 convalescent serum*

136   Convalescent serum samples (n=32) were provided by Dr. Pedro A Piedra (Baylor

137   College of Medicine, Houston, TX, USA). Samples were collected from COVID-19

138   individuals 18-79 years of age 4-6 weeks after testing positive for SARS CoV-2.

139   Symptoms ranged from asymptomatic, mild to moderate symptoms, to severe

140   symptoms requiring hospitalization. Sera were analyzed for anti-SARS-CoV-2 S IgG,

141   hACE2 receptor inhibition, and virus neutralizing antibody titers.

142   *2.9.   Histopathology*

143   Animals were euthanized 7-days following SARS-CoV-2 challenge (Day 42) and

144   lung tissues collected. Tissue were prepared for histologic examination by Experimental

145   Pathology Laboratories, Inc. (EPL, Sterling, VA). The lungs were fixed with 10%

146   formalin, paraffin embedded, and sections stained with hematoxylin and eosin (H&E) for

147   histological examination. Slides were examined for total inflammation, periarteriolar, and

148   peribronchiolar inflammation and epithelial cell denuding.

3. RESULTS

150   *3.1. Immunogenicity of NVX-CoV2373 in nonhuman primates compared to COVID-19*

151   *convalescent human sera*

152   Macaques immunized with the prime/boost regimen of 2.5, 5, and 25 µg NVX-

153   CoV2373 with 25 µg in the low and 50 µg Matrix-M1 adjuvant in the two higher doses

8

Rev08

154   induced anti-S IgG (EC_{50}) antibodies at Day 21 after a single dose (GMT = 7,810,

155   22,386 and 21,472, respectively). Two weeks following a booster immunization, anti-S

156   IgG EC_{50} titers increased to GMT EC_{50} = 163,036, 335,017 and 469,739, respectively

157   (**Figure 1A**). In contrast, SARS-CoV-2 anti-S antibody in convalescent human sera was

158   6.9- to 14.2-fold less with at GMT EC_{50} of 23,614 (**Figure 1B**). And, hACE2 receptor

159   inhibition titers of 649, 1,410, and 1,320 in 2.5, 5, and 25 µg NVX-CoV2373 dose groups

160   respectively were 5.2 – 11.2-fold higher than in convalescent sera (**Figure 1C**). Finally,

161   SARS-CoV-2 GMT neutralization antibody titers of 17,920 - 23,040 CPE_{100} in

162   immunized macaques, were 7.9 – 10.1-fold higher than in convalescent sera (**Figure**

163   **1D**).

164   *3.2. Viral load in nasal swabs and BAL*

165   To evaluate the potential efficacy of NVX-CoV2373 vaccine, macaques were

166   challenged with SARS-CoV-2 virus in upper and lower airways. Macaques in the

167   placebo group had 9,131 sgRNA copies/mL in the BAL at 2 days post challenge and

168   remained elevated at day 4 except for one animal. In contrast, immunized animals had

169   no detectable sgRNA in BAL fluid other than one animal in the low dose group at day 2

170   which cleared replicating virus RNA by day 4 (**Figure 1E**). Half of the controls had ~4

171   log10 of virus sgRNA copies in nasal swabs and in contrast, no detectable sgRNA was

172   in the nose of NVX-CoV2373 vaccinated animals (**Figure 1F**).

173   *3.3. Lung pathology*

174   Lung tissues were collected from all animals at 7 days post challenge and sections

175   examined for pathologic changes within the upper and lower airways. Consistent with

9

176   previous reports of SARS-CoV-2 infection in rhesus macaques [5-10] placebo control

177   animals had moderate to severe inflammation that involved the mucosa of the bronchi,

178   perivascular mononuclear infiltrate with mixed infiltrates of macrophages and

179   neutrophils within the alveoli. In contrast, there was little, or no inflammation observed in

180   the lungs of macaques immunized with NVX-CoV2373 vaccine 7 days post challenge

181   (**Figure 2**). These findings were consistent the absence of sgRNA in BAL fluids and

182   nasal swabs of vaccinated animals by day 4 post challenge (**Figure 1E and 1F**).

183   **Discussion**

184   Here, we report the immunogenicity and the protective efficacy of a prefusion,

185   stabilized, full-length SARS-CoV-2 S vaccine (NVX-CoV2373) in the cynomolgus

186   macaque model permissive to infection [11]. Prime and booster immunization with NVX-

187   CoV2373 vaccine with Matrix1-M adjuvant induced high levels of anti-S IgG and

188   antibodies that blocked SARS-CoV-2 spike protein binding to the hACE2 receptor and

189   neutralized the virus. Importantly, vaccinated nonhuman primates had little or no

190   detectable replicating virus (sgRNA) in either upper or lower respiratory tracks. These

191   results demonstrate a potential of NVX-CoV2373 vaccine to protect the lower

192   respiratory track against pulmonary disease and upper respiratory track against virus

193   replication thus helping to establish herd immunity and to halt the COVID-19 pandemic

194   and its devastating global impact.

195

Rev08

ENDNOTES

Acknowledgments

Author contributions

MGX, GS, GG, JHT, ADP, MJM, MBF and LE contributed to conceptualization of experiments, generation of data and analysis, and interpretation of the results. NP, JHT, BZ, and SM performed experiments. MGX, NP and KL coordinated projects. GS, GG, MBF, PAP, MGX, NP and LE contributed to drafting and making critical revisions with the help of others.

Competing interests

Authors MGX, NP, JHT, BZ, SM, KL, ADP, MJM, GG, GS and LE are current or past employees of Novavax, Inc., a for-profit organization, and these authors own stock or hold stock options. These interests do not alter the authors adherence to policies on sharing data and materials. MBF and PAP declare no competing interests.

Rev08

REFERENCES

212

213 1. Jing-Hui Tian, Nita Patel, Robert Haupt, Haixia Zhou, Stuart Weston, Holly

214   Hammond, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373

215   elicits immunogenicity in baboons and protection in mice. bioRxiv 2020; doi:

216   https://doi.org/10.1101/2020.06.29.178509

217 2. Cheryl Keech, Gary Albert, Patricia Reed, Susan Neal, Joyce S. Plested, Mingzhu

218   Zhu et al. First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein

219   Nanoparticle Vaccine. medRxiv 2020; doi:

220   https://doi.org/10.1101/2020.08.05.20168435

221 3. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, et

222   al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science

223   2020;367:1260-3. https://doi:10.1126/science.abb2507.

224 4. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.

225   Virological assessment of hospitalized patients with COVID-2019. Nature

226   2020;581:465-9. https://doi:10.1038/s41586-020-2196-x.

227 5. Shan C, Yao YF, Yang XL, Zhou YW, Gao G, Peng Y, et al. Infection with novel

228   coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques. Cell Res

229   2020;30:670-7. https://doi:10.1038/s41422-020-0364-z.

230 6. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, et al.

231   SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science

232   2020;369:812-7. https://doi:10.1126/science.abc4776.

Rev08

233   7. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated

234   vaccine candidate for SARS-CoV-2. Science 2020;369:77-81.

235   https://doi:10.1126/science.abc1932.

236   8. Neeltje van Doremalen, Teresa Lambe, Alexandra Spencer, Sandra Belij-

237   Rammerstorfer, Jyothi N. Purushotham, Julia R. Port, et al. ChAdOx1 nCoV-19

238   vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRXiv. 2020;

239   https://doi:10.1101/2020.05.13.093195.

240   9. Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, et al. DNA

241   vaccine protection against SARS-CoV-2 in rhesus macaques. Science

242   2020;369:806-11. https://doi:10.1126/science.abc6284 .

243   10. Kizzmekia S. Corbett, Barbara Flynn, Kathryn E. Foulds, Joseph R. Francica,

244   Seyhan Boyoglu-Barnum, Anne P. Werner, et al. Evaluation of the mRNA-1273

245   Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med 2020;

246   https://doi:10.1056/NEJMoa2024671.

247   11. Rockx B, Kuiken T, Herfst S, Bestebroer T, Lamers MM, Oude Munnink BB, et al.

248   Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate

249   model. Science 2020;368:1012-5. https://doi:10.1126/science.abb7314.

250

251

252   **Figure 1.**

Rev08

Figure 1. Immunogenicity of NVX-CoV2373 vaccine in cynomolgus macaques. (**A**) Groups of cynomolgus macaques (n = 4 per arm) were immunized weeks 0 and 3 with 2.5 µg NVX-CoV2373 with 25 µg Matrix-M1 or 5 µg or 25 µg NVX-CoV2373 with 50 µg Matrix-M1. Anti-spike EC_{50} IgG titers were measured weeks 0, 1, 3, and 5. Lines indicate anti-spike IgG titers for individual macaques in each group. (**B**) Anti-spike EC_{50} IgG serum titers week 5 in NVX-CoV2373 immunized NHP compared to anti-S EC_{50} IgG titers in convalescent human sera. (**C**) ACE2 inhibition IC_{50} serum titers week 5 NVX-CoV2373 immunized macaques compared to ACE2 inhibition titers in convalescent human sera, (**D**) Neutralization CPE_{100} titers against wild type SARS-CoV-2 virus week 5 NVX-CoV2373 immunized macaques compared to neutralization CPE_{100} titers in convalescent human sera, (**E**) Subgenomic RNA copies in BAL fluid days 2 and 4 post challenge SARS-CoV-2 virus in placebo and NVX-CoV2373 immunized macaques. (**F**) Subgenomic RNA copies in nasal swab samples days 2 and 4 post challenge with SARS-CoV-2 virus in placebo and NVX-CoV2373 immunized macques. Dashed horizontal line indicates the limit of detection (LOD). ConV: Convalescent serum. BAL: bronchoalveolar lavage.

15

Rev08

271 **Figure 2.**

| | Placebo | 5 µg NVX-CoV2373 + 50 µg Matrix-M1 | 25 µg NVX-CoV2373 + 50 µg Matrix-M1 |

(rows: Bronchial, Vascular, Alveoli)

Figure 2. Representative histopathology of lungs from NVX-CoV2373 vaccinated cynomolgus macaques challenged with SARS-CoV-2 (WA1 strain). Histological findings of representative placebo treated animals included eosinophils expanding the mucosa of the bronchi, perivascular mononuclear infiltrate, with mixed macrophages and neutrophils within the alveoli at 7 days post infection. In the 5 µg dose group, one animal had mild to moderate perivascular infiltrate while other animals had no remarkable findings. There were no remarkable histological changes in the bronchial, vascular or alveoli in animals vaccinated with 50 µg NVX-CoV2373. There was no evidence of exacerbated lung inflammation in NVX-CoV2373 immunized animals.

272